These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 29760763)
1. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Shah A; Northcutt J Ann Gen Psychiatry; 2018; 17():19. PubMed ID: 29760763 [TBL] [Abstract][Full Text] [Related]
2. Psychometric analysis of the Swedish panic disorder severity scale and its self-report version. Svensson M; Nilsson T; Johansson H; Viborg G; Perrin S; Sandell R Nord J Psychiatry; 2019 Jan; 73(1):58-63. PubMed ID: 30636466 [TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712 [TBL] [Abstract][Full Text] [Related]
4. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. Jacobsen P; Zhong W; Xu R; Nomikos G J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873 [TBL] [Abstract][Full Text] [Related]
5. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. Prosser JM; Yard S; Steele A; Cohen LJ; Galynker II BMC Psychiatry; 2009 May; 9():25. PubMed ID: 19470174 [TBL] [Abstract][Full Text] [Related]
6. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. Foster RH; Goa KL CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224 [TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. Papp LA J Clin Psychiatry; 2006 Oct; 67(10):1573-6. PubMed ID: 17107249 [TBL] [Abstract][Full Text] [Related]
9. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. Cao B; Park C; Rosenblat JD; Chen Y; Iacobucci M; Subramaniapillai M; Mansur RB; Zuckerman H; Lee Y; McIntyre RS J Psychopharmacol; 2019 Nov; 33(11):1388-1394. PubMed ID: 31530216 [TBL] [Abstract][Full Text] [Related]
11. An open-label study of tiagabine in panic disorder. Sheehan DV; Sheehan KH; Raj BA; Janavs J Psychopharmacol Bull; 2007; 40(3):32-40. PubMed ID: 18007567 [TBL] [Abstract][Full Text] [Related]
12. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS Front Psychiatry; 2019; 10():17. PubMed ID: 30766492 [No Abstract] [Full Text] [Related]
13. Predictors of response among patients with panic disorder treated with medications in a naturalistic follow-up: the role of adult separation anxiety. Miniati M; Calugi S; Rucci P; Shear MK; Benvenuti A; Santoro D; Mauri M; Cassano GB J Affect Disord; 2012 Feb; 136(3):675-9. PubMed ID: 22134042 [TBL] [Abstract][Full Text] [Related]
14. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. Findling RL; Robb AS; DelBello MP; Huss M; McNamara NK; Sarkis EH; Scheffer RE; Poulsen LH; Chen G; Lemming OM; Auby P J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):47-54. PubMed ID: 29035574 [TBL] [Abstract][Full Text] [Related]
16. Korean panic disorder severity scale: construct validity by confirmatory factor analysis. Lim YJ; Yu BH; Kim JH Depress Anxiety; 2007; 24(2):95-102. PubMed ID: 16845647 [TBL] [Abstract][Full Text] [Related]
17. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Kessler RC; Chiu WT; Jin R; Ruscio AM; Shear K; Walters EE Arch Gen Psychiatry; 2006 Apr; 63(4):415-24. PubMed ID: 16585471 [TBL] [Abstract][Full Text] [Related]
18. Depression does not affect the treatment outcome of CBT for panic and agoraphobia: results from a multicenter randomized trial. Emmrich A; Beesdo-Baum K; Gloster AT; Knappe S; Höfler M; Arolt V; Deckert J; Gerlach AL; Hamm A; Kircher T; Lang T; Richter J; Ströhle A; Zwanzger P; Wittchen HU Psychother Psychosom; 2012; 81(3):161-72. PubMed ID: 22399019 [TBL] [Abstract][Full Text] [Related]
19. Nocturnal sleep panic and depression: relationship to subjective sleep in panic disorder. Singareddy R; Uhde TW J Affect Disord; 2009 Jan; 112(1-3):262-6. PubMed ID: 18558437 [TBL] [Abstract][Full Text] [Related]
20. Panic disorder with and without agoraphobia: comorbidity within a half-year of the onset of panic disorder. Kikuchi M; Komuro R; Oka H; Kidani T; Hanaoka A; Koshino Y Psychiatry Clin Neurosci; 2005 Dec; 59(6):639-43. PubMed ID: 16401237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]